Chart Analysis: FibroGen (FGEN) Nears a Support Level

Over the past couple of months a key support level was formed in the chart of FibroGen Inc. (FGEN)…

FibroGen Inc (FGEN) is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company recently announced the initiation of LELANTOS, a Phase 3 trial of pamrevlumab in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy.

Take a look at the 1-year chart of FGEN with added notations…

See chart and continue reading at STOCKNEWS.com